Angiogenesis inhibitory antibodies

• US 5,677,181 A
• Filed: 07/03/1995
• Issued: 10/14/1997
• Est. Priority Date: 10/29/1992
• Status: Expired due to Term

• Current Assignee: Australian National University
• Original Assignee: Australian National University
• Inventors: Parish, Christopher Richard
• Primary Examiner(s): Feisee, Lila
• Assistant Examiner(s): Johnson, Nancy A.
• Application Number:
  US08/433,423
• Time in Patent Office: 834 Days
• Field of Search: 424/130.1, 424/152.1, 424/178.1, 424/181.1, 424/183.1, 530/387.1, 530/388.1, 530/391.3, 530/391.7, 530/389.1, 435/332
• US Class Current: 435/332
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

Antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human endothelial cells such as human umbilical vein endothelial cells and human umbilical artery endothelial cells, and conjugates of these antibodies with a toxin material or label, are useful for inhibition of angiogenesis or for treatment of angiogenesis-dependent disease.

Claims

1. An antibody which specifically binds proliferating human endothelial cells, said antibody binding proliferating human endothelial cells selected from the group consisting of proliferating human umbilical vein endothelial (HUVE) cells and human umbilical artery endothelial (HUAE) cells and not binding cells selected from the group consisting of non-proliferating HUVE cells and non-proliferating HUAE cells.

2. An antibody according to claim 1 which is a monoclonal antibody.

3. A hybridoma cell line producing a monoclonal antibody according to claim 2.

4. An antibody-conjugate comprising an antibody according to claim 1, having a toxin material or detectable label conjugated thereto.

5. An antibody-conjugate according to claim 4 wherein said antibody is a monoclonal antibody.

6. An antibody-conjugate according to claim 4, wherein said antibody is conjugated to a cytotoxic material.

7. An antibody-conjugate according to claim 6, wherein said cytotoxic material is ricin A chain, diphtheria toxin, Pseudomonas exotoxin A or idarubicin.

8. An antibody-conjugate according to claim 4, wherein said antibody is conjugated to a radioisotope label.

9. An antibody-conjugate according to claim 8, wherein said radioisotope label is technetium-99m.